| Page 27 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria

Author(s): 
Kulasekararaj AG, Lehtinen AE, Forsyth C, Gandhi S, Griffin M, Körper S, Mikala G, Muus P, Overgaard U, Patriquin CJ, Pullon H, Shen YM, Spearing R, Szer J, De la Borderie G, Duda PW, Farzaneh-Far R, Ragunathan S, Sayegh CE, Vadysirisack DD,
Primary Author: 
Kulasekararaj AG
Journal Title: 
Haematologica
Original Publication Date: 
Mar 2024
Bone Marrow Disease(s): 

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria

Author(s): 
Peffault de Latour R, Röth A, Kulasekararaj AG, Han B, Scheinberg P, Maciejewski JP, Ueda Y, de Castro CM, Di Bona E, Fu R, Zhang L, Griffin M, Langemeijer SMC, Panse J, Schrezenmeier H, Barcellini W, Mauad VAQ, Schafhausen P, Tavitian S, Beggiato E,
Primary Author: 
Peffault de Latour R
Journal Title: 
The New England Journal of Medicine
Original Publication Date: 
Mar 2024

Background: Persistent

Bone Marrow Disease(s): 

Current use of androgens in bone marrow failure disorders: a report from the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation

Author(s): 
Pagliuca S, Kulasekararaj AG, Eikema DJ, Piepenbroek B, Iftikhar R, Satti TM, Griffin M, Laurino M, Kupesiz A, Bertrand Y, Fattizzo B, Yakoub-Agha I, Aljurf M, Corti P, Massaccesi E, Lioure B, Calabuig M, Klammer M, Unal E, Wu D, Chevallier P, Forcade E,
Primary Author: 
Pagliuca S
Journal Title: 
Haematologica
Original Publication Date: 
Mar 2024

Androgens represent the historical therapeutic backbone of bone marrow failure (BMF) syndromes.

Bone Marrow Disease(s): 

Allogeneic bone marrow transplantation for aplastic anemia

Author(s): 
Storb R
Primary Author: 
Storb R
Journal Title: 
International Journal of Hematology
Original Publication Date: 
Dec 2022

After more than 60 years of intense research in allogeneic hematopoietic cell transplantation (HCT), this therapy has progressed from one that was fraught with seemingly insurmountable complications to a standard treatment of patients with

Bone Marrow Disease(s):